Agilent Technologies, Inc.
NYSE•A
CEO: Mr. Rodney Gonsalves
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1999-11-18
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Contact Information
Market Cap
$31.54B
P/E (TTM)
24.5
30.2
Dividend Yield
0.9%
52W High
$160.27
52W Low
$96.43
52W Range
Rank19Top 5.6%
6.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q1 2026 Data
Revenue
$1.80B+0.00%
4-Quarter Trend
EPS
$1.08+0.00%
4-Quarter Trend
FCF
$175.00M+0.00%
4-Quarter Trend
2026 Q1 Earnings Highlights
Key Highlights
Total Revenue Increased 7% Total net revenue reached $1,798M for the quarter, a 7% increase, driven by growth across all segments.
Agilent CrossLab Revenue Strong Agilent CrossLab segment revenue grew 9% to $758M, benefiting from strong growth in services and consumables.
Net Income Slightly Decreased Net income was $305M, a slight decrease from $318M last year, resulting in Basic EPS of $1.08.
Significant Stock Repurchase Activity Repurchased 1.050M shares for $152M under the 2024 program; $1,797M authorization remains available.
Risk Factors
Operating Margin Pressure Operating margin fell 3 percentage points to 19.7% due to higher tariffs, wage increases, and restructuring costs.
Cash Flow From Operations Cash provided by operating activities decreased to $268M from $431M last year, impacted by variable pay accruals.
Tariff Impact on Costs Tariff changes adversely impacted Q1 2026 costs of revenue, though full offset is expected during fiscal year 2026.
Increased SG&A Expenses Selling, general, and administrative expenses rose 16% due to corporate infrastructure and transformation initiative costs.
Outlook
Tariff Mitigation Strategies Expect to fully offset current tariff impact in FY2026 via supply chain optimization and targeted pricing actions.
FY25 Restructuring Completion Expect to substantially complete FY25 Plan restructuring activities by the end of fiscal year 2026.
Capital Expenditure Forecast Total capital expenditures for the current year are expected to be approximately $500M, focused on manufacturing expansion.
Continued R&D Investment Optimistic about long-term growth, continuing investment in R&D and expanding position in emerging markets globally.
Peer Comparison
Revenue (TTM)
$244.49B
$30.01B
$25.31B
Gross Margin (Latest Quarter)
82.5%
78.3%
65.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| BDX | $57.74B | 25.9 | 6.9% | 35.6% |
| TAK | $56.14B | 79.4 | 1.6% | 31.5% |
| CAH | $51.08B | 30.8 | -58.9% | 15.5% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.5%
Moderate Growth
4Q Net Income CAGR
12.4%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 26, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data